Evidence map›Paper›PMID 31327933›Full record

ArticleDigital journal of ophthalmology : DJO2019

The use of self-retained, cryopreserved amniotic membrane for the treatment of Sjögren syndrome: a case series.

Brian Shafer, Nicole M Fuerst, Mina Massaro-Giordano, Vincent Palladino, Taylor Givnish, Ilaria Macchi, Michael E Sulewski, Stephen E Orlin, Vatinee Y Bunya

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digital journal of ophthalmology : DJO, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Biological properties and surgical applications of the human amniotic membrane.Frontiers in bioengineering and biotechnology · 2022
    Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Brian ShaferDepartment of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia.
Nicole M FuerstDepartment of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia.
Mina Massaro-GiordanoDepartment of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia.
Vincent PalladinoDepartment of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia.
Taylor GivnishDepartment of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia.
Ilaria MacchiDepartment of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia.
Michael E SulewskiDepartment of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia.
Stephen E OrlinDepartment of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia.
Vatinee Y BunyaDepartment of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia.
University of Pennsylvania · USPenn Presbyterian Medical Center · US

Funding

Developing new methods for early detection of Sjogren's syndromeR01EY026972 · NEI · UNIVERSITY OF PENNSYLVANIA · PI BUNYA, VATINEE Y · 2016 to 2020
$2.0M
NEI NIH HHS R01 EY026972
6 · The paper itself

Abstract

purposeTo determine whether signs and symptoms of ocular surface disease improve after placement of a self-retained, cryopreserved amniotic membrane (CAM) in patients with Sjögren syndrome (SS).

methodsThe medical records of SS patients who received a self-retained CAM implant (Prokera or Prokera Slim; TissueTech Inc, Doral, FL) for the treatment of ocular surface disease between August 2012 and August 2016 at a single, large academic institution were reviewed retrospectively. Visual acuity, results of slit-lamp examination of the cornea and conjunctiva, and dry eye symptoms, were evaluated before and after CAM insertion.

resultsA total of 6 eyes of 6 patients (all female; mean age, 62.5 ± 13.0 years [range, 49-86 years]) were included. All patients were on topical medications at the time of the study and had signs of ocular surface dryness. There were reductions in corneal and/or conjunctival staining in 5 eyes (83%) after the CAM dissolved. All patients who completed therapy (5/5) experienced a relapse in their signs and symptoms within 1 month of removal of the CAM, with an average time to relapse of 24.6 days. Mean follow-up time was 54.5 days. Foreign body sensation and blurred vision were the most common complaints associated with the CAM implant.

conclusionsIn this small case series, self-retained CAM implantation was found to be beneficial in SS patients with ocular surface disease that is refractory to standard therapies; however, we found that the effects were temporary. Future larger studies are needed to confirm these benefits.

Indexed as

AgedAged, 80 and overAmnionConjunctivaCorneaCryopreservationFemaleHumansMaleMiddle AgedRetrospective StudiesSjogren's SyndromeVisual Acuity

Identifiers

PMID31327933
PMCPMC6636787
OpenAlexW2958002414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.